A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. - Wikidata - awgldk - TriplyDB

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

http://www.wikidata.org/entity/Q34722457

about

Radiation therapy for diffuse brainstem glioma in children and young adults DIPG in Children - What Can We Learn from the Past?Radiotherapy and "new" drugs-new side effects?Adult brainstem gliomas Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.Novel drugs in pediatric gliomas.Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem Childhood brain tumors: epidemiology, current management and future directions.Management of diffuse pontine gliomas in children: recent developments.Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.Brainstem glioma: a review.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma.Analysis of survival in pediatric high-grade brainstem gliomas: A population-based study.Molecular profiling of childhood cancer: Biomarkers and novel therapies Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes Diffuse intrinsic pontine glioma: poised for progress.Neurotoxicity of biologically targeted agents in pediatric cancer trials Biologically targeted therapeutics in pediatric brain tumors.Combining molecular targeted agents with radiation therapy for malignant gliomas Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review.Ependymomas: development of immunotherapeutic strategies.Genomic Insights into Diffuse Intrinsic Pontine Glioma.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Paediatric and adult malignant glioma: close relatives or distant cousins?Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.Diffuse intrinsic pontine glioma: a reassessment.Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.Radiotherapy for brainstem gliomas in children and adults: A single-institution experience and literature review.Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.Gliomas in children.Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.Clinical outcomes and natural history of pediatric brainstem tumors: with 33 cases follow-ups.

P2860

Q24200421-C076198E-685D-43A8-8A7B-4DA6F7E50E6F Q26777843-9354489B-7587-4856-8F4E-157EB3FF3C9B Q26861498-9F89851F-EE71-4F22-AFE7-BE8CEEF321F8 Q30457821-96B4C689-3465-411A-A1F7-81A6B6E19597 Q30652433-D276A165-64B0-48C4-8CCF-3CD01543FB18 Q33685551-EF8465D6-19D1-4FA9-8398-54A123AE3F1E Q33796170-B464D416-E6CF-49E1-80FB-6651C0D305D7 Q33970971-E2A4FE82-4841-4B09-AE71-C84F688E96EA Q34347540-37B13EFF-8D7D-4CF5-82A4-B65DD618F8A6 Q34359662-2C0AB435-D2BC-434E-9B30-BB48A5B98D21 Q34628180-23AADC61-7167-42DE-A711-846FB8AB4310 Q34848038-50EDEE83-F2FF-4407-8FEF-ECD657AE4C52 Q35230772-34BC6D05-5486-4F3B-9662-FC9EC7586C72 Q35583984-5317298A-5032-49B0-A33C-4464EBE6008B Q35791274-679991EC-CC40-4F6C-BEF8-7C0B2888F9CF Q36180087-68FEBF59-58D1-4743-A7DD-8ED2D883F111 Q36250783-19CA018C-6D57-40B8-843D-E620F7FD0EF0 Q36303824-21A8CF9E-0D38-4F01-895E-C418D441A28F Q36492719-B7A3AA12-812E-40F8-9BAA-F888223B2F78 Q36766221-4C74486D-5933-4A7A-9089-EE4398D1DBF7 Q36844744-FD7BBC88-2822-48CD-9DDD-F6D78A4896C4 Q37099594-29E05D4E-44A4-46F8-977E-400C4BA84121 Q37635839-624D377A-703A-4560-B6C4-E9C60F737485 Q37668034-DF34539B-278D-4386-A938-C91C8D839216 Q37678294-9EB374E6-22EC-4129-A30B-5B7EFA0FE26B Q37723508-601EE169-B31A-41E7-B2F1-EF21CE4393EB Q37936432-28663D1D-990C-40B0-860B-7CF9272333F2 Q38013990-E6E084EA-EFEB-452B-BC48-955B57DC0238 Q38133407-992775BB-115C-4CA3-8785-87D504C28875 Q38208998-CEA23FDF-4589-410E-BE33-18C319FB38DB Q38233425-7ED18FDF-BF18-4DCB-91F1-EA6A195A495B Q38363549-824D755F-1C5A-447F-AAE9-7E1A41E986B0 Q38583655-CFAA9D84-5E1F-4E91-9A8C-C085D490CC08 Q38758113-CE1ABB80-20E4-41DF-990A-2BD00F5861CF Q38963434-A0432718-E01D-429E-A928-D2F3CCCB7CFA Q39217689-B66A61E4-8406-4302-9D74-3C77FE18674C Q41109977-E5A30390-3B44-4790-AC58-01584A856031 Q45343976-1E93C310-E662-4ED8-8B5B-00AD9F1593A0 Q45384951-8801D801-7C8D-42FC-B516-664D437C5CC3 Q48303024-4ACBCCDE-6372-4F81-BF23-FDCC6D5B130E

P2860

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

http://www.wikidata.org/entity/Q34722457

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@ast

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@en

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@nl

type

label

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@ast

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@en

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@nl

prefLabel

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@ast

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@en

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@nl

P1433

Q34722457-ACBEE0FE-EFCE-4498-8C3E-DA61D83C7F3C

P1476

Q34722457-E4CBDE31-4641-4C1E-B2C0-02EFC3EF74E8

P2093

Q34722457-395F1093-BDEA-41ED-AF21-5809114FC1D5

Q34722457-5C1B8B1F-6B08-423F-ABBC-B7162628F429

Q34722457-686250DD-E095-4E13-B4C5-2686082E7346

Q34722457-6A6703BC-9E6F-4FAF-90F0-87D55B6BE3BD

Q34722457-70F91308-30E1-41D4-90C1-C35E82DC4587

Q34722457-8F78814E-A14A-409C-9C15-B9CE7B222524

Q34722457-E35A25E8-D68F-4032-8BA3-E1419F9E5E2C

Q34722457-FE4AA3BA-394A-4D52-B74D-6300AF013629

P2860

Q34722457-007688BD-E1A1-4D0F-A57D-590DE693B15C

Q34722457-08C447C0-FF84-4AC8-B5DE-F30EF8751DD2

Q34722457-0A7E1F21-E4D5-4AB3-AB6C-9877C34BDA79

Q34722457-0DB750CC-3A28-477D-BC37-145294839160

Q34722457-12AFB051-DE63-42EF-84AF-C0711507C371

Q34722457-1B94D8CD-0397-4633-8804-BD94B31AEA8D

Q34722457-24196406-27DA-41D7-8CFD-154C6E1AF3E9

Q34722457-28B28F3C-1B09-4BE7-ACCB-F5FB2CA785F3

Q34722457-360875FA-C126-43F8-96C2-BB609D565FB7

Q34722457-3635D304-73A5-43C6-A0CF-A4A12FC384CA

P304

Q34722457-C88F069F-8F8F-407B-AB2D-93E19030E80B

P31

Q34722457-352FF387-5120-48A9-B2DC-0D2B596A14AA

P356

Q34722457-53D47FD0-2E50-4C40-BFA6-460F58ECBED5

P433

Q34722457-3C3D21FC-AEDF-475F-B2CE-610CFBEA6923

P478

Q34722457-777BC0AC-80B5-4C4F-BECD-4B5C570AD157

P50

Q34722457-7A0A1967-641C-4DFD-B740-1BE0C9CF9B2B

Q34722457-DE699E8D-ED1A-453F-8E6D-F4C810D47973

P577

Q34722457-9C538DBB-CD1A-40D7-9087-FE84BFF81C18

P5875

Q34722457-C8582A38-40DD-4FD3-AAC1-B0DA23AAB0E3

P698

Q34722457-F8619EC0-8374-4EAB-A838-F9D4FCC80992

P932

Q34722457-D5FF2512-A79D-46D4-9D56-3B9970A69380

P356

P1433

P1476

A phase II study of gefitinib ...... iatric Brain Tumor Consortium.

@en

P2093

Anu Banerjee

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

Ian F Pollack

http://www.w3.org/2001/XMLSchema#string

J Russell Geyer

http://www.w3.org/2001/XMLSchema#string

James G Douglas

http://www.w3.org/2001/XMLSchema#string

James M Boyett

http://www.w3.org/2001/XMLSchema#string

Larry E Kun

http://www.w3.org/2001/XMLSchema#string

Tina Young Poussaint

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated genomic analysis of human glioblastoma multiforme

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Diffuse brain stem glioma. A review of stereotactic biopsies.

Diffuse brainstem glioma in children: critical review of clinical trials.

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

P304

290-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ199

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Broniscer

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49809170

http://www.w3.org/2001/XMLSchema#string

P698

21292687

http://www.w3.org/2001/XMLSchema#string

P932

3064605

http://www.w3.org/2001/XMLSchema#string